{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:53:43Z","timestamp":1791438823203,"version":"4.3.3"},"reference-count":115,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Dexcom","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/03ra42c27","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases in Sweden. Continuous glucose monitoring (CGM) is an increasingly important alternative to self-monitoring of blood glucose (SMBG), particularly for people receiving insulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To summarize the evidence for CGM in insulin-treated T2DM and conduct a policy landscape analysis of national and local guidelines to explore access to CGM in Sweden relative to other countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A scoping review was conducted to identify evidence on the clinical, patient, and economic value of CGM, supplemented with searches of Swedish and European guidelines. Current recommendations for CGM in T2DM in Sweden were compared with European-wide and country-specific recommendations. Regional recommendations and funding processes within Sweden were reviewed to examine heterogeneity in local access to CGM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Across international and Swedish studies, CGM was associated with improved clinical outcomes compared with SMBG, both for people with intensive insulin-treated T2DM and those on basal insulin only. The clinical benefits likely translate into fewer long-term diabetes complications and reduced resource utilization and budget impact versus SMBG. Health economic evaluations show that CGM can be considered a cost-effective intervention for all individuals treated with insulin in Sweden. European-wide guidance supports consideration of CGM for all insulin-treated individuals, but access in Sweden remains limited outside of the high-risk intensive insulin-treated population. This is exacerbated by regional heterogeneity in access, which partly stems from the attribution of budget responsibility to individual primary care units.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The benefits associated with CGM show that an expansion of the Swedish recommendations to cover all insulin-treated people with T2DM is warranted. Persistent regional disparities must be addressed to ensure equitable access to care for people with T2DM in Sweden. The establishment of dedicated funding mechanisms within primary care should be considered to promote more equitable and sustainable access.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15209156261442987","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:39:30Z","timestamp":1776227970000},"page":"1007-1024","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous Glucose Monitoring in Insulin-Treated Type 2 Diabetes Mellitus in Sweden: A Scoping Review and Policy Landscape Analysis"],"prefix":"10.1177","volume":"28","author":[{"given":"Johan","family":"Jendle","sequence":"first","affiliation":[{"name":"School of Medicine, Department of Medical Sciences, \u00d6rebro University, \u00d6rebro, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Adolfsson","sequence":"additional","affiliation":[{"name":"Department of Diabetes H\u00f6gsbo Hospital, Gothenburg, Sweden."},{"name":"Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-5511","authenticated-orcid":false,"given":"Jarl","family":"Hellman","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Klanger","sequence":"additional","affiliation":[{"name":"Primary Care, V\u00e4ster\u00e5s, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Rajamand Ekberg","sequence":"additional","affiliation":[{"name":"Centre for Diabetes, Academic Specialist Centre, Stockholm, Sweden."},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-025-02938-3"},{"key":"e_1_3_3_3_1","unstructured":"2.Nationella Diabetesregistret. \u00c5rsrapport 2024 \u00c5rs Resultat. Available from: https:\/\/ndr.registercentrum.se\/statistik\/arsrapporter\/p\/Skf28_I3i [Last accessed: January 2026]."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034"},{"key":"e_1_3_3_5_1","unstructured":"4.International Diabetes Federation. Global clinical practice recommendations. Available from: https:\/\/idf.org\/what-we-do\/education\/idf-clinical-practice-recommendations-for-type-2-diabetes-2025\/ [Last accessed: November 2025]."},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0100"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01254-8"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-0870-x"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12275"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16279"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002573"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/diabetology6060049"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0489"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0450"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/db21-77-LB"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02851-8"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-2194"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19976"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/ceor.S483459"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01324-x"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0075"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0174"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S007"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.04.008"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac596"},{"key":"e_1_3_3_26_1","unstructured":"25.Haute Autorit\u00e9 de sant\u00e9 (HAS). Strat\u00e9gie th\u00e9rapeutique du patient vivant avec un diab\u00e8te de type 2. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-06\/strategie_therapeutique_du_patient_vivant_avec_un_diabete_de_type_2_-_recommandations.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_27_1","unstructured":"26.Bundesamt f\u00fcr Gesundheit. Mittel- und Gegenst\u00e4ndeliste. Available from: https:\/\/www.bag.admin.ch\/de\/mittel-und-gegenstaendeliste-migel [Last accessed: December 2025]."},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70059"},{"key":"e_1_3_3_29_1","unstructured":"28.Societ\u00e0 Italiana di Diabetologia (SID) e dell\u2019Associazione dei Medici Diabetologi (AMD). Linea Guida della Societ\u00e0 Italiana di Diabetologia (SID) e dell\u2019Associazione dei Medici Diabetologi (AMD). La terapia del diabete mellito di tipo 2. Available from: https:\/\/www.siditalia.it\/pdf\/LG-379-diabete-tipo2-ed2025.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_30_1","unstructured":"29.Deutsche Diabetes Gesellschaft (DDG). Stellungnahme zum Thema. Auswahl der Glukosemessmethode. Available from: https:\/\/www.ddg.info\/fileadmin\/user_upload\/AGDT_Stellungnahme_Glukosemessmethode_220906_final.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_31_1","unstructured":"30.Suomalainen L\u00e4\u00e4k\u00e4riseura Duodecim. Tyypin 2 diabetes. Available from: https:\/\/www.kaypahoito.fi\/hoi50056 [Last accessed: December 2025]."},{"key":"e_1_3_3_32_1","unstructured":"31.Fisherman T Gustenhoff P Pedersen-Bjergaard U et al. Kontinuerlig glukosem\u00e5ling (CGM). Available from: https:\/\/endocrinology.dk\/nbv\/diabetes-melitus\/kontinuerlig-glukosemaaling-cgm-og-flash-glukosemaaling-fgm-til-boern-unge-og-voksne\/ [Last accessed: December 2025]."},{"key":"e_1_3_3_33_1","unstructured":"32.NICE. Type 2 diabetes in adults: Management\u2014NICE guideline [NG28]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng28 [Last accessed: December 2025]."},{"key":"e_1_3_3_34_1","unstructured":"33.Centers for Medicare & Medicaid Services (CMS). Glucose monitor\u2014Policy article. Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/article.aspx?articleId=52464 [Last accessed: December 2025]."},{"key":"e_1_3_3_35_1","unstructured":"34.Diabetes Canada. Reimbursement of intermittently-scanned and real-time continuous glucose monitoring systems. Available from: https:\/\/www.diabetes.ca\/advocacy\u2013policies\/our-policy-positions\/reimbursement-of-intermittently-scanned-and-real-time-continuous-glucose-monitoring-systems-1 [Last accessed: December 2025]."},{"key":"e_1_3_3_36_1","unstructured":"35.Terumo Global. Terumo announces all dexcom G6 CGM system users on insulin therapy to be covered by insurance in Japan. December 01 2022. Available from: https:\/\/www.terumo.com\/newsrelease\/detail\/20221201\/5581 [Last accessed: December 2025]."},{"key":"e_1_3_3_37_1","unstructured":"36.IDF Europe. An overview of access to diabetes care in Europe. Available from: https:\/\/www.euractiv.com\/opinion\/idf-europes-latest-publication-highlights-the-key-barriers-to-effective-diabetes-management-and-care-across-europe\/ [Last accessed: December 2025]."},{"key":"e_1_3_3_38_1","unstructured":"37.MTP-r\u00e5det. Continuous glucose monitoring in type 2 diabetes - update of recommendation for FreeStyle Libre and FreeStyle Libre 2 Recommendation and weighted assessment. Decision. Available from: https:\/\/samverkanmedicinteknik.se\/download\/18.4a8a49351969f9911881b35\/1758614787633\/Freestyle-Libre-250424.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_39_1","unstructured":"38.Region Stockholm. 042412 Blodanalysmateriel kontinuerlig glukosm\u00e4tare. Available from: https:\/\/vardgivarguiden.se\/kunskapsstod\/hjalpmedelsguiden\/behovstrappor\/vard-och-behandling\/livsuppehallande-behov\/medicinska-funktionsnedsattningar\/diabeteshjalpmedel\/kontinuerlig-glukosmatare\/ [Last accessed: December 2025]."},{"key":"e_1_3_3_40_1","unstructured":"39.Syd\u00f6stra sjukv\u00e5rdsregionen. Diabetes. Available from: https:\/\/sydostrasjukvardsregionen.se\/programomraden\/rpo-endokrina-sjukdomar\/rag-diabetes\/ [Last accessed: December 2025]."},{"key":"e_1_3_3_41_1","unstructured":"40.Region \u00d6sterg\u00f6tland. Diabetes typ 2 uppf\u00f6ljning. Available from: https:\/\/vardgivare.regionostergotland.se\/vgw\/kunskapsstod\/publikationer-kunskapsstod\/diabetes-typ-2-uppfoljning [Last accessed: December 2025]."},{"key":"e_1_3_3_42_1","unstructured":"41.Region J\u00f6nk\u00f6pings l\u00e4n. Regionala riktlinjer f\u00f6r anv\u00e4ndning av FreeStyle Libre och FreeStyle Libre 2 till personer med diabetes typ 2 i Region J\u00f6nk\u00f6pings l\u00e4n. Available from: https:\/\/folkhalsaochsjukvard.rjl.se\/api\/Evolution\/pdf\/88d716a1-b52a-48b6-86be-523dc8da69df [Last accessed: December 2025]."},{"key":"e_1_3_3_43_1","unstructured":"42.Region \u00d6rebro l\u00e4n. F\u00f6rskrivning av FreeStyle Libre vid typ 2 diabetes inom prim\u00e4rv\u00e5rd. Available from: https:\/\/vardgivare.regionorebrolan.se\/globalassets\/media\/dokument\/platina\/riktlinjer\/forskrivning-av-freestyle-libre-vid-typ-2-diabetes-inom-primarvard.538648.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03185-9"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26180"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S006"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/endocrines6030034"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16033"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2026.1767987"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06107-6"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.7326\/m16-2855"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06289-z"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15866"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15519"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7444"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2025-005469"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0390"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70008"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-03030-7"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0223-6"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2025.0227"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01516-6"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0612"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd19-0037"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9974083"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.26444\/jpccr\/75145"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01548-x"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13327"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2000.00749.x"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.10-b.s21"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.24025"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1690"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0034"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-024-00505-7"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01811-x"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01172-1"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01821-9"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01325-w"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15703"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.528"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/15209156251363576"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-025-01226-9"},{"key":"e_1_3_3_83_1","unstructured":"82.Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV). Managed introduction of medical devices. Available from: https:\/\/www.tlv.se\/in-english\/medical-devices\/managed-introduction-of-medical-devices.html [Last accessed: December 2025]."},{"key":"e_1_3_3_84_1","unstructured":"83.\u00d6sterreichischen Diabetes Gesellschaft. Diabetes Mellitus\u2014Leitinien f\u00fcr die Praxis. Available from: https:\/\/www.oedg.at\/pdf\/OEDG-Leitlinien-2023-Kurzversion.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_85_1","unstructured":"84.l\u2019Assurance Maladie. Autosurveillance du patient diab\u00e9tique: Mesure en continu du glucose interstitiel. Available from: https:\/\/www.ameli.fr\/medecin\/exercice-liberal\/memos\/troubles-endocriniens\/diabete\/prise-en-charge-et-suivi-du-patient\/suivi\/autosurveillance-du-patient-diabetique-mesure-en-continu-du-glucose-interstitiel [Last accessed: December 2025]."},{"key":"e_1_3_3_86_1","unstructured":"85.Gemeinsamer Bundesausschuss. Richtlinie Methoden vertrags\u00e4rztliche Versorgung (MVV-RL): Kontinuierliche interstitielle Glukosemessung mit Real-Time-Messger\u00e4ten (rtCGM) zur Therapiesteuerung bei insulinpflichtigem Diabetes mellitus. Available from: https:\/\/www.g-ba.de\/beschluesse\/2623\/ [Last accessed: December 2025]."},{"key":"e_1_3_3_87_1","unstructured":"86.FreeStyle Libre. Criteri di Eleggibilit\u00e0 dei Prodotti FreeStyle Libre. Available from: https:\/\/www.freestyle.abbott\/it-it\/getting-started\/costandcoverage.html [Last accessed: December 2025]."},{"key":"e_1_3_3_88_1","unstructured":"87.Zorginstituut Nederland. Vergoeding Realtime Glucose Monitoring vanuit het basispakket: Wanneer en voor wie? Available from: https:\/\/www.zorginstituutnederland.nl\/werkagenda\/stofwisseling-en-hormoonhuishouding\/realtime-glucose-monitoring [Last accessed: December 2025]."},{"key":"e_1_3_3_89_1","unstructured":"88.Diabetesvereniging Nederland. Nieuw advies Zorginstituut Nederland over vergoeding van sensoren. September 30 2024. Available from: https:\/\/www.dvn.nl\/nieuws\/nieuw-advies-zorginstituut-nederland-over-vergoeding-van-sensoren [Last accessed: December 2025]."},{"key":"e_1_3_3_90_1","unstructured":"89.Nye metoder. Sensorbaserte glukosem\u00e5lere for blodsukkerm\u00e5ling. Available from: https:\/\/www.nyemetoder.no\/metoder\/kontinuerlig-glukosemaling-og-flash-glukosemaling-indikasjon-i\/ [Last accessed: December 2025]."},{"key":"e_1_3_3_91_1","unstructured":"90.Polskiego Stowarzyszenia Diabetyk\u00f3w. Refundacja sensor\u00f3w 2025 r. (rozp. MZ z 1 III 2025). Available from: https:\/\/www.diabetyk.com\/?page_id=1443 [Last accessed: December 2025]."},{"key":"e_1_3_3_92_1","unstructured":"91.Polskiego Stowarzyszenia Diabetyk\u00f3w. Pilne zmiany refundacji w leczeniu cukrzycy. Jest odpowied\u017a Ministerstwa Zdrowia. Available from: https:\/\/diabetyk.org.pl\/pilne-zmiany-refundacji-w-leczeniu-cukrzycy-jest-odpowiedz-ministerstwa-zdrowia\/ [Last accessed: December 2025]."},{"key":"e_1_3_3_93_1","unstructured":"92.Ministerio de Sanidad. Resoluci\u00f3n de 7 de abril de 2022 de la Direcci\u00f3n General de Cartera Com\u00fan de Servicios del Sistema Nacional de Salud y Farmacia por la que se hace p\u00fablico el acuerdo de la Comisi\u00f3n de prestaciones aseguramiento y financiaci\u00f3n de 2 de marzo de 2022 sobre Sistema de monitorizaci\u00f3n de glucosa para pacientes con diabetes mellitus tipo 2 en la cartera com\u00fan de servicios del Sistema Nacional de Salud. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/prestacionesSanitarias\/CarteraDeServicios\/ContenidoCS\/docs\/Resoluc_DG__DM2_DEF.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1624-3282"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1018-9106"},{"key":"e_1_3_3_96_1","unstructured":"95.Medicare. Local coverage determination - Glucose monitors (L33822). Available from: https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?LCDId=33822 [Last accessed: December 2025]."},{"key":"e_1_3_3_97_1","unstructured":"96.Region Blekinge. Kriterier f\u00f6r anv\u00e4ndning av Freestyle Libre hos personer med diabetes typ 2 i prim\u00e4rv\u00e5rden. Available from: https:\/\/regionblekinge.se\/download\/18.55ed5411193245227ae3381d\/1732608294528\/24-201%20Kriterier%20f\u00f6r%20anv\u00e4ndning%20av%20Freestyle%20Libre%20hos%20personer%20med%20diabetes%20typ%202%20i%20prim\u00e4rv\u00e5r%20477604_3_0.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_98_1","unstructured":"97.Region Dalarna. V\u00e5rdprogram Diabetes mellitus. Available from: https:\/\/www.regiondalarna.se\/contentassets\/42802f386cc44e65a7fff976264f9905\/vardprogram-diabetes-mellitus.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_99_1","unstructured":"98.Svar p\u00e5 Interpellation\u2014CGM m\u00e4tning vid diabetes i Region G\u00e4vleborg. Available from: https:\/\/moten.lg.se\/welcome-sv\/namnder-styrelser\/regionfullmaktige\/mote-2019-09-25\/agenda\/svar-pa-interpellation-cgm-matning-vid-diabetes-i-region-gavleborg-pdf?downloadMode=open#:\u223c:text=Patienter%20som%20behandlas%20med%20b%C3%A5de%20bas%2D%20och insjuk [Last accessed: December 2025]."},{"key":"e_1_3_3_100_1","unstructured":"99.Region Halland. F\u00f6rskrivning och uppf\u00f6ljning av kontinuerlig glukosm\u00e4tning vid diabetes med FreeStyle Libre systemet inom Region Halland. Available from: https:\/\/vardgivare.regionhalland.se\/app\/plugins\/region-halland-api-styrda-dokument\/download\/get_dokument.php?documentGUID=RH-16960 [Last accessed: December 2025]."},{"key":"e_1_3_3_101_1","unstructured":"100.Region Kalmar l\u00e4n. Diabetes v\u00e5rdprogram. Intyg och hj\u00e4lpmedel. Available from: https:\/\/vardgivare.regionkalmar.se\/vard\u2013behandling\/endokrina-sjukdomar\/diabetes\/intyg-och-hjalpmedel\/# [Last accessed: December 2025]."},{"key":"e_1_3_3_102_1","unstructured":"101.Region Kronoberg. Riktlinje f\u00f6r Region Kronoberg avseende anv\u00e4ndning av FreeStyle Libre hos patienter med diabetes typ 2. Available from: https:\/\/dokpub.regionkronoberg.se\/OpenDoc.aspx?Id=208514 [Last accessed: December 2025]."},{"key":"e_1_3_3_103_1","unstructured":"102.Region Norrbotten. Freestyle Libre f\u00f6r typ 2 Diabetes. Available from: https:\/\/vis.nll.se\/process\/vard\/Dokument\/vard\/V\u00e5rdrutiner\/Diagnos\/ICD10\/Freestyle%20Libre%20f\u00f6r%20typ%202%20Diabetes.pdf#:\u223c:text=Vilka%20patienter%20med%20diabetes%20typ m\u00f6jlighet%20att%20testa%20detta%20system.&text=-%20\u00e5terkommande%20allvarliga%20hypoglykemiska%20episoder%20som 2%20vid%20diabetes%20typ%202 [Last accessed: December 2025]."},{"key":"e_1_3_3_104_1","unstructured":"103.Region Sk\u00e5ne. Anv\u00e4ndning av intermittent CGM till personer med typ 2-diabetes. Available from: https:\/\/vardgivare.skane.se\/siteassets\/1.-vardriktlinjer\/lakemedel\/riktlinjer\/lakemedelsriktlinjer\u2013-fillistning\/cgm-vid-typ-2-diabetes.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_105_1","unstructured":"104.Region S\u00f6rmland. Diabetes Gemensamma v\u00e5rdrutiner. Available from: https:\/\/samverkan.regionsormland.se\/for-vardgivare\/medicinska-omraden\/endokrina-sjukdomar\/diabetes\/gemensamma-vardrutiner\/ [Last accessed: December 2025]."},{"key":"e_1_3_3_106_1","unstructured":"105.Region Uppsala. Diabetes - Komplement till handl\u00e4ggning av diabetes folder. Available from: https:\/\/publikdocplus.regionuppsala.se\/Home\/GetDocument?containerName=e0c73411-be4b-4fee-ac09-640f9e2c5d83&reference=DocPlusSTYR-29896&docId=DocPlusSTYR-29896&filename=Diabetes%20-%20Kortfattat%20komplement%20till%20folder%20.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_107_1","unstructured":"106.Region V\u00e4rmland. Diabetes typ 2-mottagning p\u00e5 v\u00e5rdcentral. Available from: https:\/\/vidadokument.regionvarmland.se\/13076 [Last accessed: December 2025]."},{"key":"e_1_3_3_108_1","unstructured":"107.Region V\u00e4sternorrland. Utv\u00e4rdering om patient kan ha nytta av en kontinuerlig blodsockerm\u00e4tare (CGM) t.ex. FreeStyle Libre. Available from: https:\/\/www.rvn.se\/globalassets\/_vardgivarwebb\/kunskapsstod-och-rutiner\/lakemedel\/rekommendationer-och-lakemedelsval\/rekommendationer\/kontinuerlig-blodsockermatare-checklista-for-utvardering-samt-uppfoljning-i-primarvard.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_109_1","unstructured":"108.V\u00e4stra G\u00f6talandsregionen. Diabetes\u2014egenm\u00e4tning av glukos. Available from: https:\/\/mellanarkiv-offentlig.vgregion.se\/alfresco\/s\/archive\/stream\/public\/v1\/source\/available\/sofia\/ssn12865-780821730-249\/surrogate\/Diabetes%20-%20egenm\u00e4tning%20av%20glukos.pdf [Last accessed: December 2025]."},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01654-y"},{"key":"e_1_3_3_111_1","unstructured":"110.NHS Central and North West London. Formulary. Available from: https:\/\/www.cnwl.nhs.uk\/patients-and-carers\/information-about-medicines\/formulary [Last accessed: December 2025]."},{"key":"e_1_3_3_112_1","first-page":"12","article-title":"Advancing health equity in diabetes: Tools to help remove barriers to health","volume":"43","author":"Rodriguez B","year":"2023","unstructured":"111.Rodriguez B, , Aikens JK. Advancing health equity in diabetes: Tools to help remove barriers to health. J Acad Nutr Diet 2023;43:12\u201317.","journal-title":"J Acad Nutr Diet"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-024-02193-5"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-018-0819-8"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3210-y"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2020.09.006"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156261442987","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15209156261442987","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15209156261442987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:21:10Z","timestamp":1791436870000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15209156261442987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":115,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"alternative-id":["10.1177\/15209156261442987"],"URL":"https:\/\/doi.org\/10.1177\/15209156261442987","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]}}}